Rabeprazole sodium

CAS# 117976-90-6

Rabeprazole sodium

Catalog No. BCC5227----Order now to get a substantial discount!

Product Name & Size Price Stock
Rabeprazole sodium: 5mg $17 In Stock
Rabeprazole sodium: 10mg Please Inquire In Stock
Rabeprazole sodium: 20mg Please Inquire Please Inquire
Rabeprazole sodium: 50mg Please Inquire Please Inquire
Rabeprazole sodium: 100mg Please Inquire Please Inquire
Rabeprazole sodium: 200mg Please Inquire Please Inquire
Rabeprazole sodium: 500mg Please Inquire Please Inquire
Rabeprazole sodium: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Rabeprazole sodium

Number of papers citing our products

Chemical structure

Rabeprazole sodium

3D structure

Chemical Properties of Rabeprazole sodium

Cas No. 117976-90-6 SDF Download SDF
PubChem ID 14720269 Appearance Powder
Formula C18H20N3NaO3S M.Wt 381.42
Type of Compound N/A Storage Desiccate at -20°C
Synonyms LY307640 sodium
Solubility DMSO : ≥ 48 mg/mL (125.51 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
SMILES CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]
Standard InChIKey KRCQSTCYZUOBHN-UHFFFAOYSA-N
Standard InChI InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Rabeprazole sodium Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Rabeprazole sodium Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Rabeprazole sodium

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.6218 mL 13.1089 mL 26.2178 mL 52.4356 mL 65.5445 mL
5 mM 0.5244 mL 2.6218 mL 5.2436 mL 10.4871 mL 13.1089 mL
10 mM 0.2622 mL 1.3109 mL 2.6218 mL 5.2436 mL 6.5545 mL
50 mM 0.0524 mL 0.2622 mL 0.5244 mL 1.0487 mL 1.3109 mL
100 mM 0.0262 mL 0.1311 mL 0.2622 mL 0.5244 mL 0.6554 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Rabeprazole sodium

Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors. Target: Proton Pump Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.

References:
[1]. http://www.drugbank.ca/drugs/DB01129

Featured Products
New Products
 

References on Rabeprazole sodium

Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules.[Pubmed:27066697]

Drug Dev Ind Pharm. 2016 Oct;42(10):1669-77.

Rabeprazole sodium (RAB) dissolved in acidic media is accompanied by its degradation in the course of dissolution testing. To develop and establish the accumulative release profiles of ACIPHEX((R)) Sprinkle (RAB) delayed-release capsules (ACIPHEX((R)) Sprinkle) in acidic media using USP apparatus 2 (paddle apparatus) as a dissolution tester, the issues of determination of accumulative release amount of RAB in these acidic media and interference of hydroxypropylmethyl cellulose phthalate were solved by adding appropriate hydrochloric acid (HCl) into dissolution samples coupled with centrifugation so as to remove the interference and form a solution of degradation products of RAB, which is of a considerably stable ultraviolet (UV) absorbance at the wavelength of 298 nm within 2.0 h. Therefore, the accumulative release amount of RAB in dissolution samples at each sample time points could be determined by UV-spectrophotometry, and the accumulative release profiles of ACIPHEX((R)) Sprinkle in the media of pH 1.0, pH 6.0, and pH 6.8 could be established. The method was validated per as the ICH Q2 (R1) guidelines and demonstrated to be adequate for quality control of ACIPHEX((R)) Sprinkle and the accumulative release profiles can be used as a tool to guide the formulation development and quality control of a generic drug for ACIPHEX((R)) Sprinkle.

Development and validation of HPLC-DAD method for the simultaneous determination of amoxicillin, metronidazole and rabeprazole sodium. Application to spiked simulated intestinal fluid samples.[Pubmed:26024556]

Ann Pharm Fr. 2015 Sep;73(5):351-60.

This work deals with the development, validation and application of an HPLC-DAD method for the determination of a ternary mixture containing amoxicillin (AX), metronidazole (MZ) and the proton pump inhibitor Rabeprazole sodium (RB). This triple therapy is used for treatment of Helicobacter pylori infection. Effective chromatographic separation between the three drugs was achieved using Thermo Hypersil BDS-C8 (4.6x250mm, 5mum particle size) column and a mobile phase composed of phosphate buffer pH 7 and acetonitrile (70: 30, by volume). The mobile phase was pumped isocratically at a flow rate of 1 mL/min. Quantification of the analytes was based on measuring their peak areas at 230nm for both AX and RB, and at 319nm for MZ. AX, MZ and RB eluted at retention times 2.36, 3.55 and 8.72min respectively. The reliability and analytical performance of the proposed HPLC procedure were statistically validated with respect to linearity, ranges, precision, accuracy, selectivity, robustness, detection and quantification limits. The linear dynamic ranges were 25-250, 25-250 and 5-50mug/mL for AX, MZ and RB respectively with correlation coefficients>0.9998. The validated method was successfully applied to the analysis of several laboratory-prepared mixtures as well as simulated intestinal fluid samples spiked with the three drugs.

A study of selective spectrophotometric methods for simultaneous determination of Itopride hydrochloride and Rabeprazole sodium binary mixture: Resolving sever overlapping spectra.[Pubmed:25456673]

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt C:1308-15.

Itopride hydrochloride (IT) and Rabeprazole sodium (RB) are co-formulated together for the treatment of gastro-esophageal reflux disease. Three simple, specific and accurate spectrophotometric methods were applied and validated for simultaneous determination of Itopride hydrochloride (IT) and Rabeprazole sodium (RB) namely; constant center (CC), ratio difference (RD) and mean centering of ratio spectra (MCR) spectrophotometric methods. Linear correlations were obtained in range of 10-110mug/muL for Itopride hydrochloride and 4-44mug/mL for Rabeprazole sodium. No preliminary separation steps were required prior the analysis of the two drugs using the proposed methods. Specificity was investigated by analyzing the synthetic mixtures containing the two cited drugs and their capsules dosage form. The obtained results were statistically compared with those obtained by the reported method, no significant difference was obtained with respect to accuracy and precision. The three methods were validated in accordance with ICH guidelines and can be used for quality control laboratories for IT and RB.

Gastrointestinal bleed induced by a fixed dose combination of rabeprazole and diclofenac sodium.[Pubmed:25298591]

Indian J Pharmacol. 2014 Sep-Oct;46(5):555-6.

Non-steroidal anti-inflammatory drugs (NSAIDs) are known to cause gastrointestinal (GI) bleed. Co-administration of proton pump inhibitors (PPIs) has been widely suggested as one of the strategies to prevent these GI complications among NSAIDs users. Herein, we present a case of severe GI bleeding in a patient taking fixed dose combination (FDC) of rabeprazole (20 mg) and diclofenac sodium (100 SR).

Description

Rabeprazole sodium(LY307640 sodium) is an antiulcer drug in the class of proton pump inhibitors.

Keywords:

Rabeprazole sodium,117976-90-6,LY307640 sodium,Natural Products,Proton Pump, buy Rabeprazole sodium , Rabeprazole sodium supplier , purchase Rabeprazole sodium , Rabeprazole sodium cost , Rabeprazole sodium manufacturer , order Rabeprazole sodium , high purity Rabeprazole sodium

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: